International Assets Investment Management LLC Purchases New Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

International Assets Investment Management LLC acquired a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 12,126 shares of the company’s stock, valued at approximately $1,175,000.

Several other large investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its holdings in Nurix Therapeutics by 351.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company’s stock worth $58,000 after purchasing an additional 4,367 shares during the last quarter. Denali Advisors LLC bought a new stake in shares of Nurix Therapeutics during the fourth quarter worth approximately $593,000. ARK Investment Management LLC lifted its holdings in Nurix Therapeutics by 23.2% in the fourth quarter. ARK Investment Management LLC now owns 3,194,999 shares of the company’s stock valued at $32,972,000 after buying an additional 601,952 shares during the period. Raymond James & Associates boosted its stake in Nurix Therapeutics by 3.1% in the fourth quarter. Raymond James & Associates now owns 101,006 shares of the company’s stock valued at $1,042,000 after acquiring an additional 3,018 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in Nurix Therapeutics by 28.9% during the 4th quarter. SG Americas Securities LLC now owns 26,601 shares of the company’s stock worth $275,000 after acquiring an additional 5,962 shares during the period.

Nurix Therapeutics Stock Performance

Shares of NRIX opened at $13.58 on Tuesday. The stock has a 50 day simple moving average of $13.31 and a 200 day simple moving average of $9.57. Nurix Therapeutics, Inc. has a 52-week low of $4.22 and a 52-week high of $18.12. The firm has a market capitalization of $667.46 million, a PE ratio of -5.11 and a beta of 2.06.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Thursday, February 15th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.26). Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%. The company had revenue of $15.16 million during the quarter, compared to analyst estimates of $30.66 million. Equities research analysts predict that Nurix Therapeutics, Inc. will post -3.15 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Houte Hans Van sold 6,812 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $10.02, for a total value of $68,256.24. Following the sale, the chief financial officer now directly owns 68,333 shares in the company, valued at $684,696.66. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders sold 10,817 shares of company stock valued at $100,256. Company insiders own 9.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on NRIX shares. HC Wainwright reduced their price target on Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, February 20th. Robert W. Baird increased their price target on shares of Nurix Therapeutics from $24.00 to $25.00 and gave the company an “outperform” rating in a research report on Thursday, April 11th. Morgan Stanley lifted their price objective on shares of Nurix Therapeutics from $9.00 to $10.00 and gave the stock an “equal weight” rating in a research note on Monday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and issued a $31.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, April 9th. Finally, Wells Fargo & Company reduced their price target on shares of Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Friday, February 16th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $21.33.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.